AU2017364308B2 - Benzodiazolium compounds as ENaC inhibitors - Google Patents

Benzodiazolium compounds as ENaC inhibitors Download PDF

Info

Publication number
AU2017364308B2
AU2017364308B2 AU2017364308A AU2017364308A AU2017364308B2 AU 2017364308 B2 AU2017364308 B2 AU 2017364308B2 AU 2017364308 A AU2017364308 A AU 2017364308A AU 2017364308 A AU2017364308 A AU 2017364308A AU 2017364308 B2 AU2017364308 B2 AU 2017364308B2
Authority
AU
Australia
Prior art keywords
amino
methyl
benzodiazol
ium
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017364308A
Other languages
English (en)
Other versions
AU2017364308A1 (en
Inventor
Jonathan David HARGRAVE
Duncan Alexander HAY
Clive Mccarthy
Thomas Beauregard SCHOFIELD
Naomi WENT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterprise Therapeutics Ltd
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of AU2017364308A1 publication Critical patent/AU2017364308A1/en
Application granted granted Critical
Publication of AU2017364308B2 publication Critical patent/AU2017364308B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017364308A 2016-11-22 2017-11-22 Benzodiazolium compounds as ENaC inhibitors Active AU2017364308B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
GB1619694.1 2016-11-22
PCT/GB2017/053499 WO2018096325A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Publications (2)

Publication Number Publication Date
AU2017364308A1 AU2017364308A1 (en) 2019-05-23
AU2017364308B2 true AU2017364308B2 (en) 2021-03-11

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017364308A Active AU2017364308B2 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as ENaC inhibitors

Country Status (20)

Country Link
US (4) US10941149B2 (enExample)
EP (1) EP3544981B1 (enExample)
JP (1) JP6980014B2 (enExample)
KR (1) KR102517273B1 (enExample)
CN (1) CN110214141B (enExample)
AU (1) AU2017364308B2 (enExample)
CA (1) CA3043132A1 (enExample)
DK (1) DK3544981T3 (enExample)
EA (1) EA039607B1 (enExample)
ES (1) ES2890226T3 (enExample)
GB (1) GB201619694D0 (enExample)
HU (1) HUE055692T2 (enExample)
IL (1) IL266745B (enExample)
MA (1) MA46878A (enExample)
MX (1) MX389496B (enExample)
PL (1) PL3544981T3 (enExample)
PT (1) PT3544981T (enExample)
TW (1) TWI756305B (enExample)
WO (1) WO2018096325A1 (enExample)
ZA (1) ZA201902710B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
MX2021015214A (es) 2019-06-12 2022-04-06 Tmem16A Ltd Compuestos para tratar enfermedad respiratoria.
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
CN116745267A (zh) 2020-12-11 2023-09-12 跨膜蛋白16A有限公司 用于治疗呼吸系统疾病的苯并咪唑衍生物
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016113167A1 (en) * 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
WO2017221008A1 (en) * 2016-06-21 2017-12-28 Enterprise Therapeutics Limited Compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
CA2534682C (en) 2003-08-18 2013-02-26 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
KR20060115348A (ko) 2003-08-18 2006-11-08 패리온 사이언스 인코퍼레이티드 지방족 피라지노일구아니딘 나트륨 채널 차단제
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004264441A1 (en) 2003-08-18 2005-02-24 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
NZ547109A (en) * 2003-10-28 2010-03-26 Vertex Pharma Benzimidazoles useful as modulators of ion channels
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
BRPI0608581A2 (pt) * 2005-03-14 2010-01-19 Transtech Pharma Inc derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008124491A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
CN101939054B (zh) 2007-12-10 2014-10-29 诺华股份有限公司 有机化合物
AU2009246799B2 (en) 2008-02-26 2014-02-27 Parion Sciences, Inc. Poly aromatic pyrazinoylguanidine sodium channel blockers
JP2011520831A (ja) 2008-05-13 2011-07-21 ノバルティス アーゲー ３，５−ジアミノ−６−クロロ−ピラジン−２−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用
ES2535736T3 (es) 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
AU2012331274B2 (en) 2011-11-02 2017-06-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
SI2855435T1 (sl) 2012-05-29 2018-09-28 Parion Sciences Inc. Dendrimeru podobni amino amidi, ki imajo delovanje blokatorja natrijevih kanalov za zdravljenje suhih oči in drugih mukoznih bolezni
EP2897940B1 (en) 2012-09-24 2019-05-01 Boehringer Ingelheim International GmbH Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
SI2931713T1 (sl) 2012-12-17 2017-03-31 Parion Sciences, Inc. Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
JP6353032B2 (ja) 2013-04-30 2018-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法
WO2015003083A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
JP6449870B2 (ja) 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
EP3022198B1 (en) 2013-07-15 2019-09-11 Boehringer Ingelheim International GmbH Novel 5-substituted benzimidazolium compounds
WO2015007519A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel benzimidazolium compounds
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
JP6449880B2 (ja) 2013-08-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピラジンアミド化合物
US20180002312A1 (en) 2015-01-12 2018-01-04 Boehringer Ingelheim International Gmbh Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
JP6667538B2 (ja) 2015-01-12 2020-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物
US9981954B2 (en) 2015-01-12 2018-05-29 Boehringer Ingelheim International Gmbh 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors
CA2995881A1 (en) 2015-08-20 2017-02-23 Boehringer Ingelheim International Gmbh Novel annelated benzamides
AU2015406100B2 (en) 2015-08-20 2020-04-23 Boehringer Ingelheim International Gmbh Novel annelated phenoxyacetamides
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016113167A1 (en) * 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
WO2017221008A1 (en) * 2016-06-21 2017-12-28 Enterprise Therapeutics Limited Compounds

Also Published As

Publication number Publication date
US20240067653A1 (en) 2024-02-29
IL266745A (en) 2019-07-31
EP3544981A1 (en) 2019-10-02
JP2019535747A (ja) 2019-12-12
GB201619694D0 (en) 2017-01-04
HUE055692T2 (hu) 2021-12-28
EA039607B1 (ru) 2022-02-16
JP6980014B2 (ja) 2021-12-15
TW201833111A (zh) 2018-09-16
TWI756305B (zh) 2022-03-01
US10941149B2 (en) 2021-03-09
PL3544981T3 (pl) 2021-12-20
MX2019005934A (es) 2019-11-12
ZA201902710B (en) 2021-10-27
IL266745B (en) 2021-12-01
US12371436B2 (en) 2025-07-29
MX389496B (es) 2025-03-20
CN110214141B (zh) 2022-05-31
MA46878A (fr) 2019-10-02
PT3544981T (pt) 2021-09-23
NZ753048A (en) 2024-09-27
BR112019009864A2 (pt) 2019-08-27
WO2018096325A1 (en) 2018-05-31
KR102517273B1 (ko) 2023-04-03
US20210147432A1 (en) 2021-05-20
DK3544981T3 (da) 2021-09-20
KR20190084076A (ko) 2019-07-15
ES2890226T3 (es) 2022-01-18
EA201991253A1 (ru) 2019-11-29
EP3544981B1 (en) 2021-06-23
CN110214141A (zh) 2019-09-06
AU2017364308A1 (en) 2019-05-23
US20250304590A1 (en) 2025-10-02
CA3043132A1 (en) 2018-05-31
US20190315757A1 (en) 2019-10-17
US11739094B2 (en) 2023-08-29

Similar Documents

Publication Publication Date Title
AU2017364308B2 (en) Benzodiazolium compounds as ENaC inhibitors
EP3794002B1 (en) Compounds
ES2398428T3 (es) Derivados de triazol útiles para el tratamiento de enfermedades
CN103649089B (zh) 作为pi3k抑制剂的吡咯并三嗪酮
US10759785B2 (en) Compounds
US20210315893A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
EP3697788B1 (en) Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases
NL1030503C2 (nl) Octahydropyrrolo[3,4-c]-pyrroolderivaten.
HK40014276B (en) Benzodiazolium compounds as enac inhibitors
HK40014276A (en) Benzodiazolium compounds as enac inhibitors
BR112019009864B1 (pt) Compostos de benzodiazolínio, composição farmacêutica e produto compreendendo os referidos compostos, seus processos de fabricação e uso

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)